Intra Cellular Therapies Performance
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
The company retains a Market Volatility (i.e., Beta) of 0.0072, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Intra Cellular's returns are expected to increase less than the market. However, during the bear market, the loss of holding Intra Cellular is expected to be smaller as well. Intra Cellular Therapies right now retains a risk of 0.0%. Please check out Intra Cellular skewness, and the relationship between the potential upside and rate of daily change , to decide if Intra Cellular will be following its current trending patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Intra Cellular Therapies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental indicators, Intra Cellular is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 149.5 M |
Intra |
Intra Cellular Relative Risk vs. Return Landscape
If you would invest 13,187 in Intra Cellular Therapies on April 28, 2025 and sell it today you would earn a total of 0.00 from holding Intra Cellular Therapies or generate 0.0% return on investment over 90 days. Intra Cellular Therapies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Intra, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intra Cellular Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intra Cellular's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intra Cellular Therapies, and traders can use it to determine the average amount a Intra Cellular's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ITCI |
Based on monthly moving average Intra Cellular is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intra Cellular by adding Intra Cellular to a well-diversified portfolio.
Intra Cellular Fundamentals Growth
Intra Stock prices reflect investors' perceptions of the future prospects and financial health of Intra Cellular, and Intra Cellular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intra Stock performance.
| Return On Equity | -0.0858 | |||
| Return On Asset | -0.0696 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.15) % | |||
| Current Valuation | 13.06 B | |||
| Shares Outstanding | 106.52 M | |||
| Price To Earning | (6.56) X | |||
| Price To Book | 12.23 X | |||
| Price To Sales | 20.63 X | |||
| Revenue | 680.85 M | |||
| EBITDA | (116.72 M) | |||
| Cash And Equivalents | 628.74 M | |||
| Cash Per Share | 6.64 X | |||
| Total Debt | 16.98 M | |||
| Debt To Equity | 0.04 % | |||
| Book Value Per Share | 10.81 X | |||
| Cash Flow From Operations | (73.18 M) | |||
| Earnings Per Share | (0.73) X | |||
| Total Asset | 1.37 B | |||
| Retained Earnings | (1.69 B) | |||
| Current Asset | 541.82 M | |||
| Current Liabilities | 140.69 M | |||
About Intra Cellular Performance
By evaluating Intra Cellular's fundamental ratios, stakeholders can gain valuable insights into Intra Cellular's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Intra Cellular has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Intra Cellular has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.Things to note about Intra Cellular Therapies performance evaluation
Checking the ongoing alerts about Intra Cellular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intra Cellular Therapies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intra Cellular is not yet fully synchronised with the market data | |
| Intra Cellular has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 680.85 M. Net Loss for the year was (74.68 M) with profit before overhead, payroll, taxes, and interest of 387.77 M. | |
| Intra Cellular Therapies currently holds about 628.74 M in cash with (73.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64. | |
| Over 96.0% of the company shares are owned by institutional investors |
- Analyzing Intra Cellular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intra Cellular's stock is overvalued or undervalued compared to its peers.
- Examining Intra Cellular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intra Cellular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intra Cellular's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intra Cellular's stock. These opinions can provide insight into Intra Cellular's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Correlations Find global opportunities by holding instruments from different markets |